Log in to search using one of your social media accounts:

 

PCI Biotech starts dosing in Phase I extension study for bile duct cancer
Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 14, 2017 Category: Pharmaceuticals Source Type: news

Raw fish dishes in Thailand are full of deadly parasites
One of the major causes of bile duct cancer, which kills 20,000 Thais each year, is a parasitic flatworm native to the Mekong region and found in freshwater fish. (Source: the Mail online | Health)
Source: the Mail online | Health - June 28, 2017 Category: Consumer Health News Source Type: news

Avoid raw fish dishes during your holiday in Thailand!
One of the major causes of bile duct cancer, which kills 20,000 Thais each year, is a parasitic flatworm native to the Mekong region and found in freshwater fish. (Source: the Mail online | Health)
Source: the Mail online | Health - June 28, 2017 Category: Consumer Health News Source Type: news

How bile duct cancer develops and how it can be prevented
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) What promotes the development of bile duct cancer in the liver? Are these factors different from those that are responsible for the much more common hepatocellular carcinomas? Scientists from the Heidelberg and Munich have been the first to uncover the molecular causes that selectively lead to the development of bile duct cancer in mice. The researchers also discovered that antioxidants or an inhibitor of a specific key enzyme can be used to stop this cancer-promoting process. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2017 Category: Cancer & Oncology Source Type: news

FISH Beneficial for Diagnosing Cholangiocarcinoma
FISH increased sensitivity of brush cytology for cholangiocarcinoma while preserving specificity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 9, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
Title: Chemo Drug May Buy Time for Those With Bile Duct CancerCategory: Health NewsCreated: 5/18/2017 12:00:00 AMLast Editorial Review: 5/19/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 19, 2017 Category: Cancer & Oncology Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 18, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Nursing, Oncology, News, Source Type: news

Chemo Drug May Buy Time for Those with Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say Source: HealthDay Related MedlinePlus Pages: Bile Duct Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 18, 2017 Category: Consumer Health News Source Type: news

Chemo Drug, Xeloda, May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 18, 2017 Category: Cancer & Oncology Source Type: news

Capecitabine improves post-surgery survival period in bile duct cancer patients
A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 17, 2017 Category: Pharmaceuticals Source Type: news

Drug improves survival of patients with rare cancer by almost a quarter
(Cancer Research UK) Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2017 Category: Cancer & Oncology Source Type: news

Overweight young men 'more likely to get severe liver disease'
Conclusion This cohort study aimed to assess whether a high BMI in late adolescence is associated with an increased risk of severe liver disease and liver cancer in later life. The researchers generally found a higher BMI was associated with an increased risk of severe liver disease, including liver cancer. A diagnosis of type 2 diabetes during follow-up was associated with a further increased risk of severe liver disease, regardless of BMI at the start of the study. This study included a very large population, and has used reliable sources of data for medical diagnoses and cause of death. But there are limitations to ...
Source: NHS News Feed - March 21, 2017 Category: Consumer Health News Tags: Obesity Cancer Source Type: news

Vietnam War  soldiers subsequently developed bile duct cancer
Some veterans are fighting for the Department of Veterans Affairs to recognize their disease as service-related so they can receive benefits, but most claims are denied. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2016 Category: Consumer Health News Source Type: news

The relationship between vegetable & fruit consumption and gallbladder & bile duct cancer
Vegetable and fruit consumption may have a protective effect against several types of cancers. However, the effect on biliary cancers is unclear. We investigated the association of vegetable/fruit consumption with the risks of gallbladder cancer (GBC), intrahepatic bile duct cancer (IHBDC) and extrahepatic bile duct cancer (EHBDC) in a population-based prospective cohort study in Japan. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazard model, and the exposure level was categorized into quartiles, with the lowest group used as the reference. A total of 80,371 people a...
Source: Current Awareness Service for Health (CASH) - November 1, 2016 Category: Consumer Health News Source Type: news

How To Prevent Cancer Naturally
Why is it that if you’re unfortunate enough to get cancer, your only option is to see an oncologist who will almost certainly recommend radiation, surgery or chemotherapy drugs? One reason is that it’s all they know. Conventional doctors are only educated to use the tools of modern medical technology. But there’s another reason that’s very concerning… Chemotherapy drugs are making oncologists very, very rich. You see, most doctors will just write you a prescription for a drug. But not oncologists. They buy these drugs at wholesale prices then sell them to cancer patients at marked-up prices....
Source: Al Sears, MD Natural Remedies - September 29, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Cancer Source Type: news

Genetics Home Reference: cholangiocarcinoma
https://ghr.nlm.nih.gov/condition/cholangiocarcinoma (Source: NLM General Announcements)
Source: NLM General Announcements - August 23, 2016 Category: Databases & Libraries Source Type: news

FDA approves Concordia’s Photofrin 630 laser
Concordia International (NSDQ:CXRX) said it won pre-market approval from the FDA for its Photofrin 630 laser, which is designed to activate an anti-cancer drug in patients with throat and lung cancers. Oakville, Ontario-based Concordia said the device is designed to activate the drug Photofrin (porfimer sodium) in patients with esophageal cancer, Barrett’s Esophagus and non-small cell lung cancer. The Photofrin 630 laser was re-engineered to include new controls and peripheral systems, the company said. “We anticipate that these improvements could support greater adoption of PDT with Photofrin wi...
Source: Mass Device - June 30, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Food & Drug Administration (FDA) Regulatory/Compliance Concordia International Source Type: news

Medical News Today: Gut bacteria may have role in bile duct cancer
Links between gut bacteria and gastrointestinal cancer are well established. Now, scientists reveal bacteria in the bile duct may also be linked to cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 27, 2016 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Scientists discover unsuspected bacterial link to bile duct cancer
Findings of a new study could open up possibilities for more targeted therapies for bile duct cancer. A research team discovered that bile duct tissue harboured a community of diverse bacteria species. Stenotrophomonas species -- previously implicated in bile duct infections -- were found to be preferentially dwelling in tumor tissue (compared to normal tissue) of non-fluke-infected Cholangiocarcinoma (CCA) patients, highlighting their potential role in development of CCA. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 24, 2016 Category: Science Source Type: news

Delcath raises $35m in private placement
Delcath (NSDQ:DCTH) said today it inked a securities purchase agreement with an investor for $35 million in senior convertible notes and stock purchase warrants, expecting to bring in $32.2 million to support operations and ongoing clinical trials. Of the $32.2 million in proceeds, Delcath said $3 million will be immediately available, with the remaining $29.2 million subject to a cash covenant restricting it and requiring it be held by control accounts of the company. “This committed financing provides us with the resources to advance our clinical development plan through the end of 2017 while also supporting o...
Source: Mass Device - June 7, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Drug-Device Combinations Delcath Systems Inc. Source Type: news

Answer revealed to this top-missed USMLE Step 2 question
Getting ready for the United States Medical Licensing Examination® (USMLE®) Step 2 is no easy feat, but we’re sharing expert insights to help give you a leg up. Take a look at the exclusive scoop on this month’s most-missed USMLE Step 2 test prep question. Think you have what it takes to rise above your peers? Test your USMLE knowledge, and view an expert video explanation of the answer from Kaplan Medical. Once you’ve got this question under your belt, be sure to test your knowledge with other posts in this series. Ready. Set. Go. This month’s question that stumped most students:...
Source: AMA Wire - May 25, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news

UCLA study identifies risk factors for bacteria transmission from tainted scopes
Over the past few years, medical scopes contaminated with antibiotic-resistant bacteria have caused hundreds of patients who underwent a specific gastrointestinal procedure to become sick. Now, UCLA physicians have identified factors that increase the likelihood of these infections. In research published in the journal Gastrointestinal Endoscopy, the physicians report that patients face an increased risk of infection from exposure to a contaminated scope if they had a stent placed in the bile duct using a tainted scope, had a history of bile duct cancer, or were hospital inpatients at the time of the procedure. The study w...
Source: UCLA Newsroom: Health Sciences - May 21, 2016 Category: Universities & Medical Training Source Type: news

Duke cancer care in Wake County
Treatment Terms Cancer Anal cancer Bile duct cancer Bladder cancer Breast cancer Colon cancer Esophageal cancer Gallbladder cancer Kidney cancer Liver cancer Lung cancer Oral cancer Ovarian cancer Pancreatic cancer Prostate cancer Rectal cancer Skin cancers Skull base tumor Spine cancer Stomach cancer Testicular cancer Throat and voice box cancer Thyroid cancer Tracheal cancer Uterine cancer Vaginal cancer and vulvar cancer Additional SEO Keywords cancer imaging and treatment in Cary...
Source: dukehealth.org: Duke Health News - May 20, 2016 Category: Consumer Health News Authors: dg62 Source Type: news

Aspirin May Help Protect Against Bile Duct Cancer: Study
Title: Aspirin May Help Protect Against Bile Duct Cancer: StudyCategory: Health NewsCreated: 5/6/2016 12:00:00 AMLast Editorial Review: 5/9/2016 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 9, 2016 Category: Cancer & Oncology Source Type: news

Aspirin may help protect against bile duct cancer: Study
HealthDay News Regular aspirin use may lower the risk of bile duct cancer, a new study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 6, 2016 Category: Consumer Health News Source Type: news

Aspirin May Help Protect Against Bile Duct Cancer: Study
FRIDAY, May 6, 2016 -- Regular aspirin use may lower the risk of bile duct cancer, a new study suggests. The study included nearly 2,400 bile duct cancer patients and a control group of more than 4,700 people without the cancer. About 25 percent of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2016 Category: Journals (General) Source Type: news

Aspirin May Help Protect Against Bile Duct Cancer: Study
People who took it regularly were three times less likely to develop the disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 5, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Oncology, Hepatology, News, Source Type: news

Surgical Management of Intrahepatic CholangiocarcinomaSurgical Management of Intrahepatic Cholangiocarcinoma
Learn about new post-surgical options for intrahepatic cholangiocarcinoma treatment including proton beam therapy and updated chemotherapy regimens. Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Aspirin lowers bile duct cancer risk
Regular aspirin use is associated with an approximately threefold reduction in risk for the three major subtypes of cholangiocarcinoma, results of a case-control study indicate. In a study comparing... (Source: Family Practice News)
Source: Family Practice News - May 3, 2016 Category: Primary Care Source Type: news

Medical News Today: Bile duct cancer risk may be reduced with aspirin use
The risk of bile duct cancer, or cholangiocarcinoma, was reduced by up to 3.6-fold for aspirin users in a new study, providing further evidence of the drug's anticancer effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 2, 2016 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Aspirin may help prevent bile duct cancer
(Wiley) Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2016 Category: Global & Universal Source Type: news

Aspirin May Lower Risk for Bile Duct CancerAspirin May Lower Risk for Bile Duct Cancer
Observational data show that low-dose aspirin users have reduced risk for bile duct cancer in all three subtypes of cholangiocarcinoma. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 22, 2016 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

In the Loop: 'This Is Not the Farewell Tour'
Imagine receiving a terminal cancer diagnosis at age 47. Now imagine calling that diagnosis "a gift." That's how Bonnie Dinneen Hedrick describes her diagnosis with stage 3 multifocal intrahepatic cholangiocarcinoma in a recent profile in Rochester Magazine. "My life is the best it's ever been," she tells the magazine — and adds that she doesn't [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 19, 2016 Category: Databases & Libraries Source Type: news

Study: Aspirin use may prevent bile duct cancer
Stephen FellerCLEVELAND, April 19 (UPI) -- Daily aspirin use can reduce risk for bile duct cancer, researchers at the Mayo Clinic report in a recent study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 19, 2016 Category: Consumer Health News Source Type: news

Aspirin use may help prevent bile duct cancer, study finds
Aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, report scientists at the conclusion of their study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 19, 2016 Category: Science Source Type: news

Aspirin use may help prevent bile duct cancer, Mayo-led study finds
(Mayo Clinic) A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2016 Category: Global & Universal Source Type: news

Aspirin Use May Help Prevent Bile Duct Cancer
ROCHESTER, Minn. — A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology. “Our study found that individuals who took aspirin had a more than a two-and-a-half to three-and-a-half-fold lesser [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 18, 2016 Category: Databases & Libraries Source Type: news

IBD Duration Tied to Cholangiocarcinoma RiskIBD Duration Tied to Cholangiocarcinoma Risk
The duration of inflammatory bowel disease (IBD) is associated with an increased risk of cholangiocarcinoma in patients who also have primary sclerosing cholangitis, according to researchers at the Mayo Clinic in Rochester, Minnesota. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Sharing Mayo Clinic: Outdoorsman Lives Life to the Fullest After Liver Transplant
Being diagnosed with bile duct cancer that eventually necessitated a liver transplant wasn't enough to keep Steve Woodford down for long. A South African native living in Utah, Steve is professional skydiving instructor, backpacker and canyon guide in Zion National Park. He has always lived on the edge with his active outdoors lifestyle. Getting sick [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 9, 2016 Category: Databases & Libraries Source Type: news

Lucy Crossley died 18 months after developing bile duct cancer symptoms
In June, 2013, Lucy Crossley, then 27, from Leeds, suddenly developed a maddening itch all over her body, although she could find no rash or bites. (Source: the Mail online | Health)
Source: the Mail online | Health - February 23, 2016 Category: Consumer Health News Source Type: news

Ablative Radiotherapy in Intrahepatic CholangiocarcinomaAblative Radiotherapy in Intrahepatic Cholangiocarcinoma
Higher doses of radiotherapy may improve local control and overall survival in patients with inoperable intrahepatic cholangiocarcinoma. Journal of Clinical Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 10, 2016 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news

Proton Beam Therapy Improves Local Control in Liver CancerProton Beam Therapy Improves Local Control in Liver Cancer
High-dose, hypofractionated proton beam therapy provides excellent local control for patients with localized, unresectable hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC), according to results of a phase 2 study. Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 23, 2015 Category: Radiology Tags: Hematology-Oncology News Source Type: news

MACC1 gene is an independent prognostic biomarker for survival in Klatskin tumor patients
(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment is best for patients with Klatskin carcinoma, one type of bile duct cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 31, 2015 Category: Biology Source Type: news

Asbestos Puts Shipbreaking Workers at Risk for Many Cancers
This study was one of the few that involved only "shipbreaking," which is the dismantling of old ships for salvage or scrap. It also examined cancers beyond mesothelioma, a cancer caused almost exclusively by inhalation or ingestion of asbestos. The study, published in the on-line medical journal PLOS One, was linked to the Taiwan Cancer Registry and involved 4,227 workers from the 1985 Kaohsiung Shipbreaking Workers Union who belonged to the Labor Insurance Program. They were followed until 2008. There were 940 deaths and 436 cancer cases reported. Their numbers were compared to a control group of 22,135 who wor...
Source: Asbestos and Mesothelioma News - August 4, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

SWOG Trial Defines a Regimen for Biliary CancerSWOG Trial Defines a Regimen for Biliary Cancer
Adjuvant capecitabine and gemcitabine followed by radiotherapy and capecitabine was well tolerated and effective in the treatment of extrahepatic cholangiocarcinoma and gallbladder carcinoma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Delcath’s melphalan gets FDA orphan drug status to treat cholangiocarcinoma
Specialty pharmaceutical firm Delcath Systems has obtained orphan drug status from the US Food and Drug Administration (FDA) for its melphalan to treat cholangiocarcinoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 20, 2015 Category: Pharmaceuticals Source Type: news

Delcath wins FDA nod for Melphalan
Delcath (NSDQ:DCTH) said today it won Orphan Drug Designation from the FDA for melphalan, used in its hepatic delivery system to treat cholangiocarcinoma. Orphan drug designations are bestowed by the FDA on treatments for “orphan diseases”, usually defined as conditions that affect fewer than 200,000 people nationwide. The designation comes with benefits, such as tax credits, exclusivity and a waived New Drug Application user fee. The drug is at the heart of Delcath’s hepatic delivery system, a chemotherapy system that delivers the melphalan to a patients liver to treat intrahepatic cholang...
Source: Mass Device - July 20, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Drug Pumps Food & Drug Administration (FDA) Regulatory/Compliance Delcath Systems Inc. Source Type: news

The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants
Scientists to Investigate Improved Treatments and a Cure for Rare Disease – Bile Duct Cancer(PRWeb May 30, 2015)Read the full story at http://www.prweb.com/releases/Cholangiocarcinoma/05/prweb12756957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 30, 2015 Category: Pharmaceuticals Source Type: news